SGEN, CLNO, USB, UIS, CWH Stock Market Report from Stock.PR.com

Seattle Genetics Inc. (NASDAQ:SGEN) recently announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of ADCETRISTM (brentuximab vedotin) for two indications:

(1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen. The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes or survival with ADCETRIS. ADCETRIS is the first drug approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic ALCL in these settings. Seattle Genetics expects to make ADCETRIS available to patients next week. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30.

ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

The ADCETRIS approvals were based on data from two open-label, single-arm clinical trials: a pivotal trial in Hodgkin lymphoma patients who relapsed after ASCT and a pivotal trial in relapsed systemic ALCL patients. The primary endpoint of both trials was overall response rate as assessed by an independent review facility.

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Seattle Genetics’ first product, ADCETRIS™, was approved by the FDA on August 19, 2011 for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and for the treatment of patients with systemic anaplastic large cell lymphoma (ALCL) after failure of at least one prior multi-agent chemotherapy regimen.

More about SGEN at www.seattlegenetics.com

*********

Cleantech Transit, Inc., (CLNO.OB) was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector.

The main use of biomass today is as a fuel for California’s existing biomass power plants. The 30-35 facilities represent approximately 2% of the state’s electrical generation capacity.

In April 2011 Governor Jerry Brown signed into law California’s revised Renewable Portfolio Standard (RPS) that requires 33% of the state’s electricity to be sourced from renewables (including biomass) by 2020.

The recognized need to reduce wildland fire hazards combined with the reality of the commercial biomass power plant markets and the need for rural economic development has led to a renewed interest in smaller scale woody biomass utilization options that can be located closer to the fuel source. Of particular interest are systems that generate electricity by combusting synthesis gas from the gasification of biomass.

CLNO has expanded its focus to invest directly in specific green projects that can maximize shareholder value.

More about CLNO at www.cleantechtransitinc.com.

*********

U.S. Bancorp (NYSE:USB) will host the largest and longest Midwest holiday fireworks display on Sunday, July 3 beginning at dusk. The hour-long Milwaukee lakefront show will be launched from three barges located in Lake Michigan, just off the shore of Veterans Park. The fireworks will take place at approximately 9:30 p.m. and will not be rescheduled if there is severe weather.

U.S. Bancorp, a financial services holding company, provides various banking and financial services in the United States. It generates various deposit products, including checking accounts, savings accounts, money market savings, and time certificates of deposit accounts.

*********

Unisys Corporation (NYSE:UIS) said that it will release its second-quarter 2011 financial results on Monday, July 25, 2011 after the close of trading on the New York Stock Exchange. Following the release, Unisys will host a conference call with the financial community from 5:30 - 6:30 p.m. Eastern Time to discuss the results.

Unisys Corporation operates as an information technology (IT) company worldwide. The company operates in two segments, Services and Technology.

*********

CommonWealth REIT (NYSE:CWH) announced its regular quarterly common and preferred dividendsA regular quarterly common dividend of $0.50 per Common Share will be paid with respect to the results of operations for the quarter ended June 30, 2011, to holders of record of Common Shares as of the close of business on July 11, 2011, and will be distributed on or about August 25, 2011.

CommonWealth REIT is a real estate investment trust, or REIT, which primarily owns office and industrial properties located throughout the United States. CWH is headquartered in Newton, Massachusetts.